Appointments

COM DEV International Ltd. has commenced its search for a new chief executive offi cer following the decision by the company to replace John Keating. Keating has also resigned as a director of the company. “COM DEV wishes to express its gratitude for the signifi cant contribution that Mr. Keating has made to the company and wishes him well in his future endeavours,” said COM DEV’s chairman, Terry Reidel. The board of directors has appointed Mike Pley as interim CEO during the search process.

MethylGene Inc. announces the appointment of Dr. Martin Godbout as chairman of its board of directors effective immediately. Dr. Godbout has been a member of MethylGene’s board of directors

since 2002 and was the president and chief executive offi cer of Genome Canada from April 2000 to October 2009. He was also formerly the senior vice president of BioCapital and president and general manager of Societe Innovatech Quebec. Prior to that, he was a member of the board of the “Conseil de la science et de la technologies du Quebec” from October 1996 to 2004 and has been an advisory member of several Canadian biopharmaceutical venture fi rms such as SGF Sante and Royal Bank Ventures Inc. as well as a board member of the Societe Innovatech du Grand Montréal. In 2005, Dr. Godbout was named Offi cer of the Order of Canada. He was also awarded the Grand Prix Recherche from the Quebec Mental Illness Foundation for his previous work on Alzheimer’s disease in 1991, as well as a “Prix Summa” in 1994 from the Faculty of Sciences and Engineering of the Universite Laval. In 1994, he founded BioContact Quebec which has become one of the most important biopharmaceutical symposiums in North America. enGene Inc. announces that Dr. Russell J. Mumper has joined the company’s Scientifi c Advisory Board. Dr. Mumper is an internationally recognized leader in developing nanotechnologies for drug delivery and is currently the executive associate Dean for Academics and the John A. McNeill Distinguished professor at the UNC Eshelman School of Pharmacy at the University of North Carolina (UNC) at Chapel Hill. He also serves as the director of the Center for Nanotechnology in Drug Delivery at UNC. Dr. Mumper has contributed extensively to the fi elds of nano-scale drug delivery systems, drug-polymer conjugates, and trans-mucosal drug and vaccine delivery. He has also authored more than 215 scientifi c publications/abstracts and holds 38 granted and pending patents. Notably, Dr. Mumper was the fi rst scientist to demonstrate the use of chitosan as a carrier for nucleotides and holds the earliest patent in this fi eld.

Theratechnologies has appointed John-Michel T. Huss as president and chief executive offi cer of the Company. Huss has over 20 years experience in the pharmaceutical industry in various international positions and was responsible for various disease areas including diabetes and metabolism. Until recently, he was chief of staff, offi ce of the CEO, of Sanofi -Aventis in Paris. He began his career in 1990, at Merck & Co., Inc. primarily in sales and marketing in the U.S., Germany and Switzerland. In 1996, he was offered a position with F. HoffmanLa Roche as an Internal Product Manager at their Basel headquarters in Switzerland. In 1999, he joined Sanofi -Synthélabo GmbH, as Business Unit Director and has held various positions of increasing responsibility in marketing and sales. He became General Manager in Switzerland in 2007. During his tenure at Sanofi -Aventis (Sanofi Synthélabo merged with Aventis in 2004) he held positions in Germany, Canada, Switzerland and France. Huss completed his fi rst University degree in Applied Linguistics in Germany and then received an MBA in the U.S., specializing in International Business.

Industry association LifeSciences British Columbia has appointed Don Enns as the new president of the organization effective immediately. Enns has been a leader in the British Columbia life sciences industry for over 25 years, most recently as president and CEO of CANTEST Ltd., a BC-headquartered global organization providing professional analytical and clinical services in support of environmental quality, pharmaceutical, biotechnology and food safety industries as well as related projects for business and government. Enns received his MBA from UBC in 1987 and his Bachelor of Science Chemistry from TWU in 1982. He is a director for numerous local companies and non-profi t organizations involved with technology development, education, community enhancement and environmental sustainability. He currently serves as a director or committee advisor to Genome British Columbia, the World Wildlife Fund and two UBC faculties amongst other organizations.

Dr. Jeff Turnbull, Ottawa Hospital chief of staff and co-founder of the Ottawa Inner City Health program is the new president of the Canadian Medical Association

(CMA). Dr. Turnbull takes over the presidency from Dr. Anne Doig, a family physician from Saskatoon. The “passing of the torch” occurred during the association’s 143rd annual meeting in Niagara Falls, ON. Dr. Turnbull received a bachelor’s degree from the University of Toronto and his medical degree from Queen’s University. He completed an internal medicine residency and a master’s degree in education at the University of Western Ontario. For nine years, Dr. Turnbull joined the faculty at the University of Western Ontario where he combined clinical practice, education and research. Jeff Turnbull was recruited to the University of Ottawa and served as vice-dean for Medical Education for several years, before being appointed chair of the Department of Medicine, a position he held until 2008 when he became chief of staff at The Ottawa Hospital. Dr. Turnbull also served as president of the College of Physicians and Surgeons of Ontario and chaired the CMA’s Future of Medicine Project. Dr. Turnbull was also Program Director of UNESCO’s Universities in Solidarity for the Health of the Disadvantaged. Jeff Turnbull continues to practice internal medicine both at The Ottawa Hospital and at several shelters associated with Ottawa Inner City Health. In 2007 he received the Order of Canada.

Regenicin, Inc. announces that Dr. Joseph Rubinfeld, one of the four original founders of Amgen, Inc., has agreed to join the company’s board of directors. Dr. Rubinfeld will be instrumental to assisting the company’s commercialization efforts of PermaDerm™, Regenicin’s proprietary autologous cultured skin substitute intended to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures. In addition to his efforts in founding Amgen, Dr. Rubinfeld has a forty-year history in pharmaceutical and consumer product development. His accomplishments include the creation of the multi-billion dollar antibiotic Amoxicillin as well as the fi rst synthetic biodegradable detergent. He has obtained over 100 patents during his distinguished career. He began his career as a research scientist with several pharmaceutical and consumer product companies including Schering Plough and Colgate Palmolive. He served for 12 years at Bristol Myers, where in addition to developing Amoxicillin and Chephadroxil, he was instrumental in licensing their original anti-cancer line of products, including Mitomycin, Etoposide, and Bleomycin. After co-founding Amgen in 1980 and serving as its chief of operations, Dr. Rubinfeld has served as an advisor or board member to a number of companies including AVI BioPharma and Quark Pharmaceuticals. In 1991 he co-founded Supergen where he served as president and CEO until 2003 and as a member of the Board of directors until 2005. During that time he oversaw the company’s initial public offering and its rise to a multi-billion dollar market capitalization.

Dr. Martin Godbout

Dr. Jeff Turnbull. Photo: Couvrette/Ottawa